Literature DB >> 3543403

Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences.

A McLachlan, D R Milich, A K Raney, M G Riggs, J L Hughes, J Sorge, F V Chisari.   

Abstract

Amphotropic retroviral expression systems were used to synthesize hepatitis B virus surface antigen (HBsAg) and core antigen. The vectors permitted establishment of cell lines which expressed antigen from either the retroviral long terminal repeat or the mouse metallothionein-I promoter. HBsAgs were synthesized containing no pre-S sequences, pre-S(2) sequences alone, or pre-S(1) plus pre-S(2) sequences. Inclusion of pre-S(2) sequences did not affect the secretion or density of HBsAg particles but did reduce their mass by approximately 30%. Addition of pre-S(1) sequences almost completely abolished secretion of HBsAg and resulted in its localization in an aqueous-nonextractable pre- or early-Golgi cellular compartment. HBsAg was localized to the cytoplasm of the cell. This localization was unaffected by the presence of pre-S sequences in the antigen. Cell lines synthesizing hepatitis B antigens from core DNA fragments, containing or not containing precore sequences, secreted hepatitis B e antigen. However, the absence of precore DNA sequences resulted in additional synthesis of hepatitis core antigen, which was predominantly nuclear in localization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3543403      PMCID: PMC254007          DOI: 10.1128/JVI.61.3.683-692.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Nucleotide sequence of Moloney murine leukaemia virus.

Authors:  T M Shinnick; R A Lerner; J G Sutcliffe
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

3.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

4.  Electron microscopy of hepatitis B core antigen synthesized in E. coli.

Authors:  B J Cohen; J E Richmond
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

5.  Structure of mouse metallothionein-I gene and its mRNA.

Authors:  N Glanville; D M Durnam; R D Palmiter
Journal:  Nature       Date:  1981-07-16       Impact factor: 49.962

6.  Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.

Authors:  F Galibert; E Mandart; F Fitoussi; P Tiollais; P Charnay
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

7.  Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA.

Authors:  M F Dubois; C Pourcel; S Rousset; C Chany; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

8.  The conversion of hepatitis B core antigen synthesized in E coli into e antigen.

Authors:  P MacKay; J Lees; K Murray
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

9.  Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector.

Authors:  A M Moriarty; B H Hoyer; J W Shih; J L Gerin; D H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

10.  Isolation of recombinant DNA clones carrying complete integrated proviruses of Moloney murine leukemia virus.

Authors:  L Bacheler; H Fan
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

View more
  73 in total

1.  Deletions in the hepatitis B virus small envelope protein: effect on assembly and secretion of surface antigen particles.

Authors:  R Prange; R Nagel; R E Streeck
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Myristylation is involved in intracellular retention of hepatitis B virus envelope proteins.

Authors:  R Prange; A Clemen; R E Streeck
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles.

Authors:  K Ueda; T Tsurimoto; K Matsubara
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Characterization of hepatitis B virus capsid particle assembly in Xenopus oocytes.

Authors:  S Zhou; S Q Yang; D N Standring
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.

Authors:  A K Raney; D R Milich; A McLachlan
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

Review 6.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

7.  Role of peroxisome proliferator-activated receptor gamma coactivator 1alpha in AKT/PKB-mediated inhibition of hepatitis B virus biosynthesis.

Authors:  Caitlin R Ondracek; Alan McLachlan
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

8.  Hepatitis B virus p25 precore protein accumulates in Xenopus oocytes as an untranslocated phosphoprotein with an uncleaved signal peptide.

Authors:  S Q Yang; M Walter; D N Standring
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Mechanisms of inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by hepatocyte nuclear factor 3beta.

Authors:  Hong Tang; Alan McLachlan
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen.

Authors:  H Okamoto; F Tsuda; Y Akahane; Y Sugai; M Yoshiba; K Moriyama; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.